1,489,189 Shares in Lexeo Therapeutics, Inc. $LXEO Acquired by Avoro Capital Advisors LLC

Avoro Capital Advisors LLC purchased a new stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 1,489,189 shares of the company's stock, valued at approximately $6,932,175,000. Lexeo Therapeutics makes up 0.1% of Avoro Capital Advisors LLC's investment portfolio, making the stock its 26th biggest holding. Avoro Capital Advisors LLC owned about 1.81% of Lexeo Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. BlackRock Inc. bought a new stake in Lexeo Therapeutics during the second quarter valued at $26,717,000. RA Capital Management L.P. purchased a new position in shares of Lexeo Therapeutics in the 4th quarter worth about $49,650,000. Paradigm Biocapital Advisors LP purchased a new position in shares of Lexeo Therapeutics in the 4th quarter worth about $47,299,000. Balyasny Asset Management L.P. bought a new position in shares of Lexeo Therapeutics during the 2nd quarter valued at about $16,117,000. Finally, Jupiter Topco LLC bought a new position in shares of Lexeo Therapeutics during the 2nd quarter valued at about $18,409,000. 60.67% of the stock is currently owned by hedge funds and other institutional investors.

Lexeo Therapeutics Stock Performance

Shares of LXEO stock opened at $5.01 on Thursday. Lexeo Therapeutics, Inc. has a one year low of $3.99 and a one year high of $10.99. The company has a market capitalization of $411.05 million, a price-to-earnings ratio of -4.36 and a beta of 1.46. The company's 50-day moving average is $4.74 and its 200 day moving average is $5.48.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.01). As a group, research analysts predict that Lexeo Therapeutics, Inc. will post -1.18 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on the company. Chardan Capital upgraded Lexeo Therapeutics to a "strong-buy" rating in a research report on Tuesday, July 28th. JPMorgan Chase & Co. decreased their price objective on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an "overweight" rating on the stock in a research report on Thursday, June 25th. Weiss Ratings raised shares of Lexeo Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, August 13th. Finally, Wall Street Zen cut shares of Lexeo Therapeutics from a "hold" rating to a "strong sell" rating in a report on Saturday, August 15th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $18.75.

Insider Transactions at Lexeo Therapeutics

In other Lexeo Therapeutics news, insider Narinder Pal Bhalla sold 22,306 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $4.42, for a total value of $98,592.52. Following the completion of the sale, the insider owned 82,194 shares in the company, valued at approximately $363,297.48. This represents a 21.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Richard Nolan Townsend sold 25,947 shares of Lexeo Therapeutics stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $4.48, for a total value of $116,242.56. Following the sale, the chief executive officer directly owned 377,817 shares in the company, valued at $1,692,620.16. This trade represents a 6.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 66,326 shares of company stock worth $299,817. Insiders own 2.00% of the company's stock.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source